Trial reportCancer medicine2019
The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials.
Trial report in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Treatment and survival outcomes for patients with follicular lymphoma and POD24: a systematic review and meta-analysis.Blood advances · 2026Pooled it
- Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis.Annals of hematology · 2022Pooled it
- Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.Nature medicine · 2022Trial
- The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials.Cancer medicine · 2019Trial
- Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.Blood advances · 2026Review
- Effect of POD24 on the prognosis of follicular and other indolent B-cell non-hodgkin lymphomas.Annals of hematology · 2025Review
- A machine learning-based model to predict POD24 in follicular lymphoma: a study by the Chinese workshop on follicular lymphoma.Biomarker research · 2025Article
- The POD24 challenge: where do we go from here for early progressors?Hematology. American Society of Hematology. Education Program · 2024Review
- Personalised therapy in follicular lymphoma - is the dial turning?Hematological oncology · 2024Review
- Article
- B-cell non-Hodgkin lymphomas.Lancet (London, England) · 2024Review
- Unraveling the complexity of follicular lymphoma: insights and innovations.American journal of cancer research · 2024Review
- Efficacy and safety-related factors of BTK inhibitors as a bridge to CAR-T therapy in R/R FL.Annals of hematology · 2023Article
- Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden.HemaSphere · 2023Article
- The prognostic index PRIMA-PI combined with Ki67 as a better predictor of progression of disease within 24 months in follicular lymphoma.Frontiers in oncology · 2023Article
- Sex differences in lymphoma incidence and mortality by subtype: A population-based study.American journal of hematology · 2023Article
- Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab.Cancer management and research · 2023Review
- Screening of Adverse Prognostic Factors and Construction of Prognostic Index in Previously Untreated Concurrent Follicular Lymphoma and Diffuse Large B-Cell Lymphoma.BioMed research international · 2022Article
- Early Relapse in First-Line Follicular Lymphoma: A Review of the Clinical Implications and Available Mitigation and Management Strategies.Oncology and therapy · 2021Review
- Cost-effectiveness analysis of allogeneic versus autologous stem cell transplant versus chemo-immunotherapy for early relapse of follicular lymphoma within 2 years of initial therapy.Bone marrow transplantation · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 2 countries.
Funding
Abstract
Follicular lymphoma (FL) patients treated with firstline R-CHOP who experience progression of disease (POD) within 2 years have a shorter survival than those who do not have POD within 2 years. Whether this observation holds for patients treated initially with biologic immunotherapy alone is unknown. We performed a retrospective analysis of 174 patients pooled from three frontline rituximab (R)-based nonchemotherapy doublet trials: R-galiximab (Anti-CD80, CALGB 50402), R-epratuzumab (Anti-CD22, CALGB 50701), and R-lenalidomide (CALGB 50803) to determine outcomes of early progressors and risk factors for early POD, defined as progression within 24 months from study entry. Twenty-eight percent (48/174) of patients had early POD. After adjusting for the Follicular Lymphoma International Prognostic Index (FLIPI), patients with early POD from study entry had a worse OS compared with patients who did not progress within 2 years (HR = 4.33 (95% CI 1.50-12.5), P = 0.007). For early POD, the 2-year survival was 80% vs 99% for nonearly POD, and the 5-year survival was 74% vs 90%, respectively. These findings suggest that the adverse survival of patients with early POD may be independent of initial treatment modality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.